Dolutegravir Effective for Pediatric HIV in Low-Income Countries

Dolutegravir, an antiretroviral medication, continues to demonstrate robust effectiveness in suppressing HIV among children and adolescents, even in resource-limited settings. Recent analyses confirm high rates of viral suppression and offer insights into factors influencing treatment outcomes, bolstering confidence in dolutegravir-based regimens as a cornerstone of pediatric and adolescent HIV care.

Expanding Access, Sustaining Control

The findings, emerging from studies conducted in Tanzania and other regions, underscore the importance of dolutegravir (DTG) as a preferred first-, second-, and third-line treatment option for children and adolescents living with HIV. Tanzania adopted DTG into its national HIV treatment protocols in 2019, a move that has significantly impacted viral load suppression rates. A retrospective cohort analysis of over 63,000 children and adolescents on DTG-based regimens between 2019 and 2021 revealed a viral suppression rate of 91.64% [1]. This success is particularly notable given the challenges of maintaining consistent treatment adherence and access to care in many low- and middle-income countries.

Viral load suppression, meaning reducing the amount of HIV in the blood to undetectable levels, is crucial not only for the health of the individual but also for preventing further transmission of the virus. Achieving and maintaining viral suppression is a key component of the global “95-95-95” targets set by UNAIDS, aiming to finish the AIDS epidemic by 2030.

Factors Influencing Treatment Success

The Tanzanian study identified several factors associated with higher chances of viral suppression. Adolescents aged 15-19 years and those in earlier WHO clinical stages (I and II) demonstrated improved outcomes. Notably, individuals who had ever received a multi-month prescription of antiretroviral therapy also showed a significant increase in viral suppression rates [1]. This suggests that strategies to improve adherence, such as simplifying medication schedules and reducing the frequency of clinic visits, can play a vital role in treatment success.

Conversely, certain factors were linked to lower rates of viral suppression. Younger individuals (aged 10-14 years), those who were previously unsuppressed before starting DTG, and those with a longer duration on ART (more than 24 months) exhibited lower suppression rates. Non-retention in care, severe malnutrition, and residing in the coastal zone were also associated with decreased viral suppression. These findings highlight the demand for targeted interventions to address the specific challenges faced by these populations.

Understanding WHO Clinical Staging

The World Health Organization (WHO) clinical staging system is used to classify the severity of HIV disease based on clinical symptoms and signs. Stage I represents asymptomatic HIV infection, while Stage II includes mild symptoms such as enlarged lymph nodes and skin rashes. More advanced stages (III and IV) are associated with more severe immune suppression and opportunistic infections.

Real-World Evidence from Across Africa

Beyond Tanzania, research from a six-country African cohort (Botswana, Eswatini, Lesotho, Malawi, Tanzania, and Uganda) further reinforces the positive impact of dolutegravir-based therapy. A study involving nearly 11,800 children and adolescents found that DTG rapidly achieved and consistently maintained viral load suppression over extended periods [3]. The average follow-up time on DTG was 22.4 months, with the majority of participants receiving a coformulated DTG regimen (tenofovir/lamivudine/DTG). Viral load suppression was defined as HIV RNA below 1000 copies.

This study also revealed that DTG-based regimens were effective across different age groups, with approximately 56% of participants being female. While a small percentage of participants transferred to other care centers or were lost to follow-up, the overall durability of viral suppression remained high.

Adolescent-Specific Challenges and Considerations

A cross-sectional study from Soroti City, Uganda, specifically focused on adolescents on dolutegravir-based antiretroviral therapy, highlighting unique challenges within this population [2]. While DTG has become a preferred regimen for adolescents globally, understanding the factors contributing to viral load non-suppression in this age group is crucial for optimizing treatment strategies.

Adolescence is a period of significant physical, emotional, and social changes, which can impact adherence to medication and engagement in care. Addressing these challenges requires a holistic approach that considers the specific needs of adolescents living with HIV, including psychosocial support, peer mentoring, and confidential counseling services.

What Comes Next: Ongoing Surveillance and Guidance Updates

The continued success of dolutegravir in suppressing HIV among children and adolescents necessitates ongoing surveillance to monitor treatment outcomes and identify emerging challenges. Researchers are actively investigating factors that may contribute to virological failure, such as drug resistance mutations and pharmacokinetic interactions. The BIPAI Network Centres in Africa, for example, are continuing to analyze data from DTG-treated youth to assess long-term outcomes and inform clinical practice.

National HIV programs and international organizations, such as the WHO, regularly review the latest evidence and update treatment guidelines accordingly. As fresh data become available, adjustments may be made to treatment regimens, monitoring strategies, and adherence support interventions. Healthcare providers should stay informed about the most current recommendations to ensure that children and adolescents living with HIV receive the best possible care.

Further research is also needed to explore the potential benefits of innovative approaches, such as long-acting injectable antiretroviral medications, which could further simplify treatment regimens and improve adherence. These advancements hold promise for enhancing the quality of life and long-term health outcomes for children and adolescents living with HIV.